Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 33,170 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: COVID-19
Interventions: Tocilizumab, Placebo; Drug
Lead sponsor: Queen's Medical Center; Other
Eligibility: 18 Years to 95 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Hidradenitis Suppurativa
Interventions: Spesolimab - solution for infusion, Placebo matching spesolimab - solution for infusion, Spesolimab- solution for injection, Placebo matching to spesolimab- solution for injection; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Los Angeles, California • Indianapolis, Indiana • Rochester, Minnesota + 2 more

Conditions: Genital Herpes Simplex Type 2
Interventions: Matrix-M2, GEN-003, Placebo; Biological · Drug
Lead sponsor: Genocea Biosciences, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 8
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more

Conditions: Diabetic Retinopathy
Interventions: doxycycline monohydrate, placebo; Drug
Lead sponsor: Thomas Gardner; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Healthy Study Participants
Interventions: glovadalen, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Glendale, California

Conditions: Schizophrenia and Predominant Negative Symptoms
Interventions: SPD489 (lisdexamfetamine dimesylate), Placebo matching SPD489 (lisdexamfetamine dimesylate); Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 27
States / cities: Little Rock, Arkansas • Anaheim, California • Costa Mesa, California + 21 more

Conditions: Degenerative Arthritis and Postoperative Pain
Interventions: Placebo, Gapabentin; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 70 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Chronic Plaque Psoriasis
Interventions: Secukinumab 300 mg, Placebo; Drug · Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 12
States / cities: Los Angeles, California • Santa Ana, California • Rockville, Maryland + 8 more

Conditions: Hot Flushes, Menopause, Premature, Obesity, Vitamin D Deficiency
Interventions: Vitamin D, Placebo; Dietary Supplement · Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Ebola Hemorrhagic Fever
Interventions: AVI-7537, Normal Saline Solution (NSS); Drug · Other
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: End-Stage Renal Disease Patients on Hemodialysis
Interventions: Fish oil capsules, matched placebo capsules; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 82 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: TRN-157, Placebo; Drug
Lead sponsor: Theron Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Cypress, California

Conditions: Improve Photoaging Signs
Interventions: CE Ferulic, Sham Comparator, 1927nm (Clear and Brilliant Perméa®); Drug · Device
Lead sponsor: Goldman, Butterwick, Fitzpatrick and Groff; Other
Eligibility: 30 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Spinal Cord Injuries, Urinary Bladder, Neurogenic
Interventions: Oxybutynin Chloride IR, Mirabegron; Drug
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 70 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Pain
Interventions: Celecoxib, Sugar Pill; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Posttraumatic Stress Disorder
Interventions: mifepristone, placebo; Drug
Lead sponsor: James J. Peters Veterans Affairs Medical Center; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Depemokimab, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 1,196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 42
States / cities: Newport Beach, California • Lakewood, Colorado • Brandon, Florida + 35 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: AZD9668, AZD9668 Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 838 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Fullerton, California • Valparaiso, Indiana • Council Bluffs, Iowa + 6 more

Conditions: Obesity
Interventions: Alcohol challenge test Alcohol visit first, Alcohol challenge test Placebo visit first; Other
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: B Cells-Tumors, B Cell Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Large B-Cell Diffuse Lymphoma of Bone (Diagnosis)
Interventions: Idelalisib 100 MG, Placebo Oral Tablet; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Fragile X Syndrome
Interventions: AFQ056, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 8
States / cities: Sacramento, California • Decatur, Georgia • Chicago, Illinois + 5 more

Conditions: Alcohol Abuse, Alcohol Dependence
Interventions: Ondansetron, placebo ondansetron; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metabolic Syndrome, Inflammation, Hypertriglyceridemia, Obesity
Interventions: Aronia berry juice, Sham comparator; Dietary Supplement · Other
Lead sponsor: Montana State University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: Candidiasis
Interventions: Caspofungin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

Evaluating New Formulation of Therapeutic HSV-2 Vaccine

Evaluation of Doxycycline Verses Placebo for the Treatment of Severe Nonproliferative or Mild or Moderate Proliferative Diabetic Retinopathy

A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants

Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms

Effect of Gabapentin on Orthopedic Pain

Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis

The Role of Vitamin D in Menopause: Relationship to Menopausal Symptoms in Body Composition

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers

A Pilot Study of Fish Oil Supplementation in Hemodialysis Patients

Single Ascending Dose Study of TRN-157 in Healthy Subjects

Skin Care Regimen for Improving Photoaging Signs on the Face

Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury

Effectiveness of Celecoxib After Surgical Sperm Retrieval

Trial of Mifepristone in Combat Veterans With Posttraumatic Stress Disorder

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium

Effects of Alcohol After Bariatric Surgery

Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies

Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome

Ondansetron, Alcohol Use, and Alcohol-Related Symptoms In HIV+ Persons

Impacts of Aronia on Inflammation and the Gut Microbiome

Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care Units